Bombay Generics Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-07-2024
- Paid Up Capital ₹ 5.00 M
as on 26-07-2024
- Company Age 35 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.87 M
as on 26-07-2024
- Satisfied Charges ₹ 5.23 Cr
as on 26-07-2024
- Revenue 1359.34%
(FY 2023)
- Profit 484.83%
(FY 2023)
- Ebitda 233.89%
(FY 2023)
- Net Worth 72.04%
(FY 2023)
- Total Assets 36.27%
(FY 2023)
About Bombay Generics
The Corporate was formerly known as Osho Pharma Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹0.87 M. The company has closed loans amounting to ₹5.23 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bakulkumar Padia, Krunal Sanghavi, Snehalbhai Shah, and Five other members serve as directors at the Company.
- CIN/LLPIN
U24231GJ1989PTC012305
- Company No.
012305
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bombay Generics?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bakulkumar Padia  | Director | 05-Jun-1989 | Current |
| Krushnakant Bhalodia | Director | 01-Feb-2021 | Current |
| Dimpal Bhalodiya | Director | 01-Feb-2021 | Current |
| Krunal Sanghavi | Director | 11-Jul-2016 | Current |
| Snehalbhai Shah | Director | 11-Jul-2016 | Current |
| Bharatkumar Patel | Director | 11-Jul-2016 | Current |
Financial Performance of Bombay Generics.
Bombay Generics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1359.34% increase. The company also saw a substantial improvement in profitability, with a 484.83% increase in profit. The company's net worth Soared by an impressive increase of 72.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bombay Generics?
In 2023, Bombay Generics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zeon Biotech Private LimitedActive 6 years 8 monthsAnkurkumar Bhalodiya, Krushnakant Bhalodia and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Gujrat State Financial Corporation Creation Date: 19 Jan 1990 | ₹0.87 M | Open |
Others Creation Date: 02 Sep 2023 | ₹4.00 Cr | Satisfied |
Union Bank Of India Creation Date: 12 Sep 2005 | ₹1.15 Cr | Satisfied |
How Many Employees Work at Bombay Generics?
Unlock and access historical data on people associated with Bombay Generics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bombay Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bombay Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
